---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-023589"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T14:45:44.541355+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protara CMO Jathin Bandari resigns effective April 11; interim oversight assigned

## Summary
- CMO Jathin Bandari resigns effective April 11, 2024 to explore academic opportunities; consulting through July 11.
- Severance includes $365,386 lump sum (9 months salary), $164,424 bonus, COBRA for 9 months, and pro-rata vesting of 11,993 options + 5,886 RSUs.
- Interim oversight: Jacqueline Zummo (SVP & Chief Scientific Ops Officer) leads medical staff, advised by board member Richard Levy, M.D.
- Company plans to search for a new Chief Medical Officer.

## SEC filing metadata
- accession: 0001213900-24-023589
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390024023589/0001213900-24-023589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390024023589/ea0202028-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-023589
- JSON: https://secwatch.observer/filing/0001213900-24-023589.json
- Plain text: https://secwatch.observer/filing/0001213900-24-023589.txt

## Key facts
- Executive change
  Jathin Bandari resigned as Chief Medical Officer at Protara Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On March 18, 2024, Protara Therapeutics, Inc. (the “Company”) announced that Jathin Bandari, M.D., Chief Medical Officer of the Company, will be resigning from the Company to explore other opportunities, including devoting more time to academic work, effective as of April 11, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390024023589/0001213900-24-023589-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.